Bivin & Associates’s Merck MRK Stock Holding History

Bivin & Associates’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$55K	Hold	600	–	–	0.06%	71
2022 Q1	$49K	Sell	600 -25	-4%	-$1.97K	0.04%	80
2021 Q4	$48K	Buy	+625	New	+$49.8K	0.04%	87

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bivin & Associates's MRK Position: Q2 2022 in Review

Bivin & Associates held its Merck (MRK) position steady in Q2 2022 at 600 shares worth $55K. The position accounts for 0.06% of the portfolio, ranked #71.

Bivin & Associates first reported a position in MRK in Q4 2021 and has held it in 3 quarters since. 3,014 funds tracked by Wall St. Rank hold MRK as of Q2 2022.

Bivin & Associates held 600 shares of Merck worth $55K as of Q2 2022.
Bivin & Associates left its Merck share count unchanged in Q2 2022.
Merck made up 0.06% of Bivin & Associates's portfolio in Q2 2022, its #71 holding.
Bivin & Associates first reported a position in Merck in Q4 2021 and has held it in 3 quarters since.
3,014 funds tracked by Wall St. Rank held Merck as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.